Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study

被引:120
作者
Bagatell, Rochelle [1 ]
London, Wendy B.
Wagner, Lars M.
Voss, Stephan D.
Stewart, Clinton F.
Maris, John M.
Kretschmar, Cynthia
Cohn, Susan L.
机构
[1] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA
基金
美国国家卫生研究院;
关键词
HIGH-RISK NEUROBLASTOMA; TOPOISOMERASE-I; SOLID TUMORS; PEDIATRIC-PATIENTS; PROTRACTED IRINOTECAN; XENOGRAFT MODELS; ORAL IRINOTECAN; EWING SARCOMA; CPT-11; TRIAL;
D O I
10.1200/JCO.2010.31.7107
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose This phase II study was conducted to determine the response rate associated with use of irinotecan and temozolomide for children with relapsed/refractory neuroblastoma. Patients and Methods Patients with relapsed/refractory neuroblastoma measurable by cross-sectional imaging (stratum 1) or assessable by bone marrow aspirate/biopsy or metaiodobenzylguanidine (MIBG) scan (stratum 2) received irinotecan (10 mg/m2/dose 5 days a week for 2 weeks) and temozolomide (100 mg/m2/dose for 5 days) every 3 weeks. Response was assessed after three and six courses using International Neuroblastoma Response Criteria. Of the first 25 evaluable patients on a given stratum, five or more patients with complete or partial responses were required to conclude that further study would be merited. Results Fifty-five eligible patients were enrolled. The objective response rate was 15%. Fourteen patients (50%) on stratum 1 and 15 patients (56%) on stratum 2 had stable disease. Objective responses were observed in three of the first 25 evaluable patients on stratum 1 and five of the first 25 evaluable patients on stratum 2. Less than 6% of patients experienced >= grade 3 diarrhea. Although neutropenia was observed, less than 10% of patients developed evidence of infection while neutropenic. Conclusion The combination of irinotecan and temozolomide was well tolerated. The objective response rate of 19% in stratum 2 suggests that this combination may be effective for patients with neuroblastoma detectable by MIBG or marrow analysis. Although fewer objective responses were observed in patients with disease measurable by computed tomography/magnetic resonance imaging, patients in both strata seem to have derived clinical benefit from this therapy. J Clin Oncol 29:208-213. (C) 2010 by American Society of Clinical Oncology
引用
收藏
页码:208 / 213
页数:6
相关论文
共 27 条
[1]   A NEW I-123 MIBG WHOLE-BODY SCAN SCORING METHOD-APPLICATION TO THE PREDICTION OF THE RESPONSE OF METASTASES TO INDUCTION CHEMOTHERAPY IN STAGE-IV NEUROBLASTOMA [J].
ADY, N ;
ZUCKER, JM ;
ASSELAIN, B ;
EDELINE, V ;
BONNIN, F ;
MICHON, J ;
GONGORA, R ;
MANIL, L .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (02) :256-261
[2]  
Blaney S, 2001, CLIN CANCER RES, V7, P32
[3]   REVISIONS OF THE INTERNATIONAL CRITERIA FOR NEUROBLASTOMA DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT [J].
BRODEUR, GM ;
PRITCHARD, J ;
BERTHOLD, F ;
CARLSEN, NLT ;
CASTEL, V ;
CASTLEBERRY, RP ;
DEBERNARDI, B ;
EVANS, AE ;
FAVROT, M ;
HEDBORG, F ;
KANEKO, M ;
KEMSHEAD, J ;
LAMPERT, F ;
LEE, REJ ;
LOOK, AT ;
PEARSON, ADJ ;
PHILIP, T ;
ROALD, B ;
SAWADA, T ;
SEEGER, RC ;
TSUCHIDA, Y ;
VOUTE, PA .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) :1466-1477
[4]   Irinotecan and Temozolomide for Ewing Sarcoma: The Memorial Sloan-Kettering Experience [J].
Casey, Denise A. ;
Wexler, Leonard H. ;
Merchant, Melinda S. ;
Chou, Alexander J. ;
Merola, Pamela R. ;
Price, Anita P. ;
Meyers, Paul A. .
PEDIATRIC BLOOD & CANCER, 2009, 53 (06) :1029-1034
[5]   Disseminated neuroblastoma in children older than one year at diagnosis: Comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma [J].
De Bernardi, B ;
Nicolas, B ;
Boni, L ;
Indolfi, P ;
Carli, M ;
di Montezemolo, LC ;
Donfrancesco, A ;
Pession, A ;
Provenzi, M ;
di Cataldo, A ;
Rizzo, A ;
Tonini, GP ;
Dallorso, S ;
Conte, M ;
Gambini, C ;
Garaventa, A ;
Bonetti, F ;
Zanazzo, A ;
D'Angelo, P ;
Bruzzi, P .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1592-1601
[6]   Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children [J].
Furman, WL ;
Stewart, CF ;
Poquette, CA ;
Pratt, CB ;
Santana, VM ;
Zamboni, WC ;
Bowman, LC ;
Ma, MK ;
Hoffer, FA ;
Meyer, WH ;
Pappo, AS ;
Walter, AW ;
Houghton, PJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (06) :1815-1824
[7]   Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry [J].
Garaventa, Alberto ;
Parodi, Stefano ;
De Bernardi, Bruno ;
Dau, Daniela ;
Manzitti, Carla ;
Conte, Massimo ;
Casale, Fiorina ;
Viscardi, Elisabetta ;
Bianchi, Maurizio ;
D'Angelo, Paolo ;
Zanazzo, Giulio Andrea ;
Luksch, Roberto ;
Favre, Claudio ;
Tamburini, Angela ;
Haupt, Riccardo .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (16) :2835-2842
[8]  
HOUGHTON PJ, 1993, CANCER RES, V53, P2823
[9]  
Houghton PJ, 2000, CLIN CANCER RES, V6, P4110
[10]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481